Research progress of diabetes mellitus complicated with chronic inflammatory demyelinating polyneuropathy

doi:10.11958/20230448

Abstract

Abstract:

In recent years, the results of epidemiological research findings on chronic inflammatory demyelinating polyneuropathy (CIDP) in patients with diabetes mellitus (DM) are quite different, and its correlation is still controversial. Nevertheless, due to the high incidence and treatability of CIDP in DM patients, accurate diagnosis and differentiation of DM-CIDP are of great value for guiding clinical drug use. In terms of clinical manifestations, it can be distinguished by age of onset, disease duration, blood glucose control level and main symptom characteristics. Supplementary diagnostic methods frequently involve evaluating cerebrospinal fluid protein levels, demyelination patterns in electrophysiological tests and neuroimaging studies. Additionally, neuropathological examination and specific serum antibodies can provide more diagnostic support for distinguishing DM-CIDP. Furthermore, a positive response to immunomodulatory and/or immunosuppressive therapies supports the diagnosis of DM-CIDP. By comprehensively evaluating clinical manifestations, electrophysiological characteristics, laboratory tests, neuropathology, imaging, and treatment responses, the accuracy of the differential diagnosis for DM-CIDP can be improved.

Key words: diabetes mellitus, chronic inflammatory demyelinating polyradiculopathy, research advancements, differential diagnosis

CLC Number:

R745，R741.04

References 43

[1]	CERNEA S, RAZ I. Management of diabetic neuropathy[J]. Metabolism, 2021, 123:154867. doi:10.1016/j.metabol.2021.154867.
[2]	VAN DEN BERGH P, VAN DOORN P A, HADDEN R, et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy:Report of a joint Task Force-Second revision[J]. J Peripher Nerv Syst, 2021, 26(3):242-268. doi:10.1111/jns.12455.
[3]	LEHMANN H C, BURKE D, KUWABARA S. Chronic inflammatory demyelinating polyneuropathy:update on diagnosis,immunopathogenesis and treatment[J]. J Neurol Neurosurg Psychiatry, 2019, 90(9):981-987. doi:10.1136/jnnp-2019-320314.
[4]	KOIKE H, NISHI R, IKEDA S, et al. Ultrastructural mechanisms of macrophage-induced demyelination in CIDP[J]. Neurology, 2018, 91(23):1051-1060. doi:10.1212/WNL.0000000000006625.
[5]	CHEN Y, TANG X. Chronic inflammatory demyelinating polyradiculoneuropathy in association with concomitant diseases:identification and management[J]. Front Immunol, 2022, 13:890142. doi:10.3389/fimmu.2022.890142.
[6]	KUWABARA S, TSUNEYAMA A, MISAWA S. Chronic inflammatory demyelinating polyneuropathy and diabetes[J]. J Neurol Neurosurg Psychiatry, 2020, 91(10):1035-1036. doi:10.1136/jnnp-2020-324399.
[7]	FERRAZ DE OLIVEIRA I, CORREIA I, URZAL J, et al. Chronic inflammatory demyelinating polyradiculoneuropathy and diabetes:a case report[J]. Cureus, 2022, 14(9):e29390. doi:10.7759/cureus.29390.
[8]	VALENTIN M, COULTAS R, SOTTILE E. Chronic inflammatory demyelinating polyneuropathy (CIDP) in diabetes mellitus:a diagnostic dilemma[J]. Cureus, 2022, 14(5):e25332. doi:10.7759/cureus.25332.
[9]	LAUGHLIN R S, DYCK P J, MELTON L J 3rd, et al. Incidence and prevalence of CIDP and the association of diabetes mellitus[J]. Neurology, 2009, 73(1):39-45. doi:10.1212/WNL.0b013e3181aaea47.
[10]	SHARMA K R, CROSS J, FARRONAY O, et al. Demyelinating neuropathy in diabetes mellitus[J]. Arch Neurol, 2002, 59(5):758-765. doi:10.1001/archneur.59.5.758.
[11]	BRIL V, BLANCHETTE C M, NOONE J M, et al. The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy[J]. J Diabetes Complications, 2016, 30(7):1401-1407. doi:10.1016/j.jdiacomp.2016.05.007.
[12]	APPELTSHAUSER L, MESSINGER J, STARZ K, et al. Diabetes mellitus is a possible risk factor for nodoparanodopathy with antiparanodal autoantibodies[J]. Neurol Neuroimmunol Neuroinflamm, 2022, 9(3):e1163. doi:10.1212/NXI.0000000000001163.
[13]	RAJABALLY Y A, PERIC S, COBELJIC M, et al. Chronic inflammatory demyelinating polyneuropathy associated with diabetes:a European multicentre comparative reappraisal[J]. J Neurol Neurosurg Psychiatry, 2020, 91(10):1100-1104. doi:10.1136/jnnp-2020-322971.
[14]	DUNNIGAN S K, EBADI H, BREINER A, et al. The characteristics of chronic inflammatory demyelinating polyneuropathy in patients with and without diabetes--an observational study[J]. PLoS One, 2014, 9(2):e89344. doi:10.1371/journal.pone.0089344.
[15]	DUNNIGAN S K, EBADI H, BREINER A, et al. Comparison of diabetes patients with "demyelinating" diabetic sensorimotor polyneuropathy to those diagnosed with CIDP[J]. Brain Behav, 2013, 3(6):656-663. doi:10.1002/brb3.177.
[16]	LOTAN I, HELLMAN M A, STEINER I. Diagnostic criteria of chronic inflammatory demyelinating polyneuropathy in diabetes mellitus[J]. Acta Neurol Scand, 2015, 132(4):278-283. doi:10.1111/ane.12394.
[17]	REYNOLDS J, SACHS G, STAVROS K. Chronic inflammatory demyelinating polyradiculoneuropathy(CIDP):clinical features,diagnosis,and current treatment strategies[J]. R I Med J (2013), 2016, 99(12):32-35.
[18]	CHIÒ A, PLANO F, CALVO A, et al. Comorbidity between CIDP and diabetes mellitus:only a matter of chance?[J]. Eur J Neurol, 2009, 16(6):752-754. doi:10.1111/j.1468-1331.2009.02598.x.
[19]	KOBESSHO H, OISHI K, HAMAGUCHI H, et al. Elevation of cerebrospinal fluid protein in patients with diabetes mellitus is associated with duration of diabetes[J]. Eur Neurol, 2008, 60(3):132-136. doi:10.1159/000144083.
[20]	DUNNIGAN S K, EBADI H, BREINER A, et al. Conduction slowing in diabetic sensorimotor polyneuropathy[J]. Diabetes Care, 2013, 36(11):3684-3690. doi:10.2337/dc13-0746.
[21]	ALCANTARA M, NGO M, DE LA CRUZ J, et al. Temporal dispersion and duration of the distal compound muscle action potential do not distinguish diabetic sensorimotor polyneuropathy from chronic inflammatory demyelinating polyneuropathy[J]. Front Neurol, 2022, 13:872762. doi:10.3389/fneur.2022.872762.
[22]	中华医学会神经病学分会. 慢性炎性脱髓鞘性多发性神经根神经病诊治中国专家共识2022[J]. 中华神经科杂志, 2023, 56(2):125-132.
	Chinese Society of Neurology. Chinese consensus for diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy 2022[J]. Chinese Journal of Neurology, 2023, 56(2):125-132. doi:10.3760/cma.j.cn113694-20220627-00507.
[23]	VALLAT J M, MATHIS S. Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies[J]. Brain Pathol, 2023:e13184. doi:10.1111/bpa.13184. [Epub ahead of print].
[24]	GORSON K C, ROPPER A H, ADELMAN L S, et al. Influence of diabetes mellitus on chronic inflammatory demyelinating polyneuropathy[J]. Muscle Nerve, 2000, 23(1):37-43.
[25]	DOPPLER K, WERNER C, SOMMER C. Disruption of nodal architecture in skin biopsies of patients with demyelinating neuropathies[J]. J Peripher Nerv Syst, 2013, 18(2):168-176. doi:10.1111/jns5.12023.
[26]	DOPPLER K, FRANK F, KOSCHKER A C, et al. Nodes of Ranvier in skin biopsies of patients with diabetes mellitus[J]. J Peripher Nerv Syst, 2017, 22(3):182-190. doi:10.1111/jns.12224.
[27]	PUPE C, DIECKMANN G, DORNAS R, et al. Corneal confocal microscopy in patients with distal symmetric polyneuropathy compared to controls[J]. Arq Neuropsiquiatr, 2022, 80(8):812-821. doi:10.1055/s-0042-1755231.
[28]	SCHNEIDER C, BUCHER F, CURSIEFEN C, et al. Corneal confocal microscopy detects small fiber damage in chronic inflammatory demyelinating polyneuropathy (CIDP)[J]. J Peripher Nerv Syst, 2014, 19(4):322-327. doi:10.1111/jns.12098.
[29]	FLEISCHER M, LEE I, ERDLENBRUCH F, et al. Corneal confocal microscopy differentiates inflammatory from diabetic neuropathy[J]. J Neuroinflammation, 2021, 18(1):89. doi:10.1186/s12974-021-02130-1.
[30]	WU F, WANG W, ZHAO Y, et al. MR neurography of lumbosacral nerve roots:Diagnostic value in chronic inflammatory demyelinating polyradiculoneuropathy and correlation with electrophysiological parameters[J]. Eur J Radiol, 2020, 124:108816. doi:10.1016/j.ejrad.2020.108816.
[31]	CHEN H, HUANG X, BAO Y, et al. The diagnostic value of quantitative assessment of MR neurography in chronic inflammatory demyelinating polyradiculoneuropathy:a systematic review and meta-analysis[J]. Br J Radiol, 2023, 96(1151):20221037. doi:10.1259/bjr.20221037.
[32]	VAEGGEMOSE M, HAAKMA W, PHAM M, et al. Diffusion tensor imaging MR neurography detects polyneuropathy in type 2 diabetes[J]. J Diabetes Complications, 2020, 34(2):107439. doi:10.1016/j.jdiacomp.2019.107439.
[33]	SU X, KONG X, KONG X, et al. Multisequence magnetic resonance neurography of brachial and lumbosacral plexus in chronic inflammatory demyelinating polyneuropathy:correlations with electrophysiological parameters and clinical features[J]. Ther Adv Neurol Disord, 2023, 16:17562864221150540. doi:10.1177/17562864221150540.
[34]	DÉCARD B F, PHAM M, GRIMM A. Ultrasound and MRI of nerves for monitoring disease activity and treatment effects in chronic dysimmune neuropathies - Current concepts and future directions[J]. Clin Neurophysiol, 2018, 129(1):155-167. doi:10.1016/j.clinph.2017.10.028.
[35]	TAN C Y, YAHYA M A, GOH K J, et al. Nerve ultrasound score in chronic inflammatory demyelinating polyneuropathy[J]. Medicina (Kaunas), 2023, 59(4):747. doi:10.3390/medicina59040747.
[36]	TAN C Y, ARUMUGAM T, RAZALI S, et al. Nerve ultrasound can distinguish chronic inflammatory demyelinating polyneuropathy from demyelinating diabetic sensorimotor polyneuropathy[J]. J Clin Neurosci, 2018, 57:198-201. doi:10.1016/j.jocn.2018.08.031.
[37]	WIESKE L, MARTíN-AGUILAR L, FEHMI J, et al. Serum contactin-1 in CIDP:a cross-sectional study[J]. Neurol Neuroimmunol Neuroinflamm, 2021, 8(5):e1040. doi:10.1212/NXI.0000000000001040.
[38]	MARTÍN-AGUILAR L, LLEIXÀ C, PASCUAL-GOÑI E. Autoimmune nodopathies,an emerging diagnostic category[J]. Curr Opin Neurol, 2022, 35(5):579-585. doi:10.1097/WCO.0000000000001107.
[39]	KARAM C. Chronic inflammatory demyelinating polyradiculoneuropathy:five new things[J]. Neurol Clin Pract, 2022, 12(3):258-262. doi:10.1212/CPJ.0000000000001150.
[40]	JANN S, BRAMERIO M A, BERETTA S, et al. Diagnostic value of sural nerve matrix metalloproteinase-9 in diabetic patients with CIDP[J]. Neurology, 2003, 61(11):1607-1610. doi:10.1212/01.wnl.0000096174.86850.7f.
[41]	RAJABALLY Y A. Long-term immunoglobulin therapy for chronic inflammatory demyelinating polyradiculoneuropathy[J]. Muscle Nerve, 2015, 51(5):657-661. doi:10.1002/mus.24554.
[42]	ANDRUSIÓW S, PAWLAK Z, STAŃCZYKIEWICZ B, et al. Chronic inflammatory demyelinating polyradiculoneuropathy in patients with diabetes mellitus-treatment with intravenous immunoglobulins:A systematic review[J]. Biomed Pharmacother, 2023, 164:114974. doi:10.1016/j.biopha.2023.114974.
[43]	ABRAHAM A, ALABDALI M, QRIMLI M, et al. Treatment responsiveness in CIDP patients with diabetes is associated with higher degrees of demyelination[J]. PLoS One, 2015, 10(10):e0139674. doi:10.1371/journal.pone.0139674.